Land: Armenien
Sprog: engelsk
Kilde: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
aciclovir
KRKA d.d.
J05AB01
aciclovir
250mg
powder for solution for infusion
(5) glass vial
Prescription
Registered
2022-05-31
1. NAME OF THE MEDICINAL PRODUCT Virolex ® 250 mg powder for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 250 mg aciclovir as sodium salt. Excipients with known effect: - sodium: 1.01 mmol (23.3 mg)/vial For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for solution for infusion. White or almost white lyophilized powder practically free from foreign matter. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Virolex ® 250 mg powder for solution for infusion is indicated for the treatment of_ Herpes simplex_ and _Varicella zoster_ infections in immunocompromised patients. Virolex ® 250 mg powder for solution for infusion is indicated for the prophylaxis of_ Herpes _ _simplex_ infections in immunocompromised patients. Virolex ® 250 mg powder for solution for infusion is indicated for the treatment of recurrent _Varicella _ _zoster_ infections and severe initial _genital herpes_ in non-immunocompromised patients. Virolex ® 250 mg powder for solution or infusion is indicated for the treatment of herpes encephalitis. Virolex ® 250 mg powder for solution for infusion is indicated for the treatment of_ Herpes _ _simplex_ infections in the neonate. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults_ Patients with_ Herpes simplex_ (except herpes encephalitis) or recurrent _Varicella zoster_ infections should be given Virolex ® 250 mg powder for solution for infusion in doses of 5 mg/kg body weight every eight hours provided renal function is not impaired (see Dosage in renal impairment). Immunocompromised patients with_ Varicella zoster_ infections or patients with herpes encephalitis should be given Virolex ® 250 mg powder for solution for infusion in doses of 10 mg/kg body weight every 8 hours provided renal function is not impaired (see Dosage in renal impairment). In obese patients dosed with intravenous aciclovir based on their actual body weight, higher plasma concentrations may be obtained (see 5.2 Pharmacokinetic properties). CON Læs hele dokumentet